Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: A Dutch population-based study
In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). This study's objective was to investigate whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. DLBCL patients ≥18 years, diagnosed between 2014 and 2018, who received at least 1 cycle of rituximab combined with cyclophosphamide,... Mehr ...
Verfasser: |
Brink, Mirian
Kahle, Xaver U.
Vermaat, Joost S. P.
Zijlstra, Josee M.
Chamuleau, Martine
Kersten, Marie José
Durmaz, Mujde
Plattel, Wouter J.
Lugtenburg, Pieternella J.
Stevens, Wendy
Mous, Rogier
de Vries, Elisabeth G. E.
van der Poel, Marjolein W. M.
Panday, Prashant V. Nannan
Huls, Gerwin
van Meerten, Tom
Nijland, Marcel |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2021 |
Reihe/Periodikum: |
Brink , M , Kahle , X U , Vermaat , J S P , Zijlstra , J M , Chamuleau , M , Kersten , M J , Durmaz , M , Plattel , W J , Lugtenburg , P J , Stevens , W , Mous , R , de Vries , E G E , van der Poel , M W M , Panday , P V N , Huls , G , van Meerten , T & Nijland , M 2021 , ' Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: A Dutch population-based study ' , Blood , vol. 5 , no. 15 , pp. 2958-2964 . https://doi.org/10.1182/BLOODADVANCES.2021004295 |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-28638828 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://research.vumc.nl/en/publications/f450fc6e-f6a0-443e-9c49-bb1655c138db |